| Literature DB >> 26251696 |
Tatiana V Cohen1, Gina M Many2, Bryan D Fleming3, Viola F Gnocchi2, Svetlana Ghimbovschi2, David M Mosser3, Eric P Hoffman2, Terence A Partridge2.
Abstract
BACKGROUND: Loss-of-function mutations in the dysferlin gene (DYSF) result in a family of muscle disorders known collectively as the dysferlinopathies. Dysferlin-deficient muscle is characterized by inflammatory foci and macrophage infiltration with subsequent decline in muscle function. Whereas macrophages function to remove necrotic tissue in acute injury, their prevalence in chronic myopathy is thought to inhibit resolution of muscle regeneration. Two major classes of macrophages, classical (M1) and alternative (M2a), play distinct roles during the acute injury process. However, their individual roles in chronic myopathy remain unclear and were explored in this study.Entities:
Keywords: Cell-cell interactions; Dysferlin; LGMD2B; Macrophages; Muscular dystrophy; Myoblasts; Skeletal muscle
Year: 2015 PMID: 26251696 PMCID: PMC4527226 DOI: 10.1186/s13395-015-0048-4
Source DB: PubMed Journal: Skelet Muscle ISSN: 2044-5040 Impact factor: 4.912
Fig. 1Characterization of M1 and M2 macrophages in response to differential stimuli. Bone marrow-derived macrophages were either unstimulated (Mϕ), stimulated with LPS, to induce M1, or IL-4 to induce the M2a phenotypes, respectively. a M1 phenotype validation using qRT-PCR for IL-12, b TNFα, and c iNOS. d ELISA analysis for IL-12/23p40 in M1, M2a, or control (Mϕ) macrophages. e Gene expression of Fizz-1 by qRT-PCR in M1, M2a, or control (Mϕ) macrophages. f Gene expression of IL-4 by qRT-PCR in M1, M2a, or control (Mϕ) macrophages
qRT-PCR primers used in the study
| Forward | Reverse | |
|---|---|---|
| Arg-1 | 5′-ATGGAAGAGACCTTCAGCTAC-3′ | 5′-GCTGTCTTCCCAAGAGTTGGG-3′ |
| CCR2 | 5′-ACACCCTGTTTCGCTGTAGG-3′ | 5′-CCTGGAAGGTGGTCAAGAAG-3′ |
| Fizz-1 | 5′-TCCCAGTGAATACTGATGAGA-3′ | 5′-CCACTCTGGATCTCCCAAGA-3′ |
| Ifng | 5′-CATTGAAAGCCTAGAAAGTCTG-3′ | 5′-CTCATGGAATGCATCCTTTTTCG-3′ |
| IL-1β | 5′-TGGGCCTCAAAGGAAAGAAT-3′ | 5′-CAGGCTTGTGCTCTGCTTGT-3′ |
| IL-4 | 5′-CATCGGCATTTTGAACGAGGTCA-3′ | 5′-CTTATCGATGAATCCAGGCATCG-3′ |
| IL-10 | 5′-CCAGTTTTACCTGGTAGAAGTGATG-3′ | 5′-TGTCTAGGTCCTGGAGTCCAGCAGAC-3′ |
| IL-12 | 5′-ATGGCCATGTGGGAGCTGGAG-3′ | 5′-TTTGGTGCTTCACACTTCAGG-3′ |
| Inos | 5′-TGGGAATGGAGACTGTCCCAG-3′ | 5′-GGGATCTGAATGTGATGTTTG-3′ |
| MCP-1 | 5′-AGGTCCCTGTCATGCTTCTG-3′ | 5′-GCTGCTGGTGATCCTCTTGT-3′ |
| Myf5 | 5′-GCTCGGATGGCTCTGTAGAC-3′ | 5′-GAACAGCAGCTTTGACAGCA-3′ |
| MyoD | 5′-GGCTACGACACCGCCTACTA-3′ | 5′-GCTCCACTATGCTGGACAGG-3′ |
| Myogenin | 5′-CTGACCCTACAGACGCCCAC-3′ | 5′-TGTCCACGATGGACGTAAGG-3′ |
| TNFa | 5′-GTTCTATGGCCCAGACCCTCACA-3′ | 5′-TCCCAGGTATATGGGCTCATACC-3′ |
| YM-1 | 5′-GGGCATACCTTTATCCTGAG-3′ | 5′-CCACTGAAGTCATCCATGTC-3′ |
| S18 | 5′-TAGCCTTCGCCATCACTGCC TTA-3′ | 5′-AACCTGGCTGTACTTCCCATCCTT-3′ |
Fig. 2Ongoing satellite cell proliferation and macrophage infiltrate in uninjured Bla/J muscle. a Immunofluorescence staining of uninjured 3-month-old WT and Bla/J skeletal muscle. Upper panels mice were treated with BrdU in the drinking water for 7 days. Frozen muscle sections were immunostained with anti-laminin (blue) and anti-BrdU (green) antibodies. Nuclei were detected by propidium iodide (PI, red). Bottom panels muscle sections were immunostained with an anti-F4/80 (green) antibody and nuclei were detected by DAPI staining (blue). b Proliferating cells quantitated in WT and Bla/J muscle are shown as percent of myonuclei that are BrdU-positive (proliferating). n = 3 non-overlapping fields from three mice. c Quantitation of the number of F4/80-positive macrophages in muscle per mm2. n = 3 non-overlapping fields each from three mice. d Expression of M1-specific markers using qRT-PCR in WT (black) and Bla/J (white) uninjured muscle. e Expression of M2-specific markers in WT (black) and Bla/J (white) muscle using qRT-PCR. n = 3 mice per data point. Data are shown as means ± SEM. *P < 0.05; **P < 0.01. Scale, 50 μm
Fig. 3Response to injury is attenuated in Bla/J muscle compared with WT. a H&E staining of WT (left) and Bla/J (right) muscle on day 7 after injury. b Fiber cross-sectional areas (CSA) from WT (black) and Bla/J (white) on day 7 after injury. Fiber diameter distribution of Bla/J muscle is shifted to the left. Residual tattoo ink (blue staining) can still be seen in the injured Bla/J muscle. c Immunofluorescence staining for BrdU (green) and laminin (blue) on indicated days following notexin injury in WT or Bla/J TA muscle. Nuclei were detected with propidium iodide (PI, red). d Quantitation of BrdU-positive nuclei on day 11 after injury shown as percent of BrdU-positive cells over total myonuclei. e Immunofluorescence staining for F4/80 (green) on indicated days following notexin injury in WT or Bla/J TA muscle. Nuclei were detected with DAPI (blue). f Number of F4/80-positive macrophages per mm2 on indicated days after injury. n = 3. Expression of M1-specific markers IFNγ (g) and TNFα (h) and M2-specific markers Arg-1 (i) and YM1 (j) using qRT-PCR on indicated days following injury. Data are shown as means ± SEM. *P < 0.05. Scale bar, 50 μm
Fig. 4Co-culture of A/J and WT myoblasts with M1 and M2a macrophages. a Diagram of myoblast-macrophage co-cultures. H-2K cells are plated in a 6-well dish and macrophages are plated in the top TranswellTM chamber. Soluble factors secreted by both macrophages and myoblasts can be exchanged in the culture medium. b Desmin immunostaining of dysferlin-deficient (A/J, left column) and dysferlin-sufficient (WT, right column) myoblasts after 3 days of co-culture with differentially polarized macrophages: LPS treated (M1), IL-4 treated (M2a), LPS+OVA-IC treated (M2b), or untreated (Mϕ). Scale, 50 μm. c % Fusion index in 3-day-old co-cultures of WT and A/J myoblasts with WT mice-derived macrophages obtained by dividing the number of nuclei in myotubes by total myonuclei. d Total number of cells in 3-day-old co-cultures with WT mice-derived macrophages. e % Fusion index in 3-day-old co-cultures of WT and A/J myoblasts with Bla/J mice-derived macrophages. n = 3 independent experiments. Data are shown as means ± SEM; ANOVA, *P < 0.05; ***P < 0.001
Fig. 5Cytokines secreted in myoblast-macrophage co-cultures. ELISA analysis of 3-day old WT co-culture supernatants showing expression of IL-10 (a) and IL-12 (b) in differentially polarized macrophages from WT (black bars) or Bla/J (white bars) mice. c Cytokine arrays performed on supernatants of 3-day-old WT myoblasts co-cultured without macrophages (white) or with WT mice-derived Mϕ (black), M1 (light grey), or M2a (dark grey) macrophages showing expression of M1-specific cytokines. d MSD IL-4 assay performed on supernatants of 1-day-old WT (white) or A/J (black) myoblasts that were either cultured alone (none) or co-cultured with WT mice-derived M1 or M2a macrophages. Data are shown as means ± SEM. n = 3; *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 6Illumina Gene array analysis of myoblasts co-cultured with macrophages. Venn diagrams showing gene subsets in WT (a) or A/J (b) myoblasts that were differentially regulated by co-culture with M1 only (green), by M2a only (red), or in both co-cultures (overlap). ANOVA, P < 0.01. Transcriptional networks activated by co-culture with M1 (c) or M2a (d) in A/J (red) and WT (blue) myoblasts sorted by z-score. z-score >1.5 or <1.5 indicates activated and inhibited networks, respectively. e, f Partek clustering analysis showing genes expressed in WT control myoblasts, A/J control myoblasts and WT or A/J myoblasts co-cultured with M1 (e), or M2a (f). Blue indicates downregulated; red indicates upregulated
Transcripts modulated in A/J vs. WT myoblasts co-cultured with M1 macrophages
| Gene symbol | Description | WT-M1 vs. WT | AJ vs. WT | AJ-M1 vs. AJ |
|---|---|---|---|---|
|
| Interferon, alpha-inducible protein 27 | 16.32 | 2.41 | 17.75 |
|
| Interferon-induced protein with tetratricopeptide repeats 3 | 10.49 | 1.75 | 3.44 |
|
| Complement component 2 | 2.88 | 2.63 | n/a |
|
| Interferon-induced transmembrane protein 1 | 2.86 | 1.76 | n/a |
|
| Matrix metallopeptidase 2 | 2.77 | 2.54 | n/a |
|
| Interleukin 7 | 2.62 | 1.69 | n/a |
|
| Histocompatibility 2, T region locus 23 | 2.56 | 4.41 | n/a |
|
| Interferon-induced transmembrane protein 3 | 2.50 | 1.65 | n/a |
|
| Vitamin D (1,25-dihydroxyvitamine D3) receptor | 2.37 | 2.18 | n/a |
|
| Tumor necrosis factor, alpha-induced protein 2 | 2.28 | 1.57 | n/a |
|
| Colony stimulating factor 1 | 2.25 | 1.81 | n/a |
|
| Chemokine (C-C motif) ligand 9 | 2.23 | 1.99 | 2.79 |
|
| Latent transforming growth factor beta binding protein 1 | 2.20 | 1.53 | n/a |
|
| Phosphodiesterase 4B, cAMP-specific | 2.14 | 1.61 | 1.73 |
|
| Histocompatibility 2, Q region locus 5 | 2.00 | 2.63 | n/a |
|
| Solute carrier family 1 (glial high affinity glutamate transporter), member 3 | 1.99 | 5.59 | n/a |
|
| Angiopoietin-like 4 | 1.98 | 1.93 | n/a |
|
| GTP cyclohydrolase 1 | 1.94 | 2.48 | 3.14 |
|
| Brain-derived neurotrophic factor | 1.93 | 1.54 | n/a |
|
| Purinergic receptor P2X, ligand-gated ion channel 4 | 1.86 | 1.82 | n/a |
|
| TGFB-induced factor homeobox 1 | 1.82 | 2.38 | n/a |
|
| Serpin peptidase inhibitor, clade H (heat shock protein 47) | 1.76 | 1.53 | 1.64 |
|
| Signal transducer and activator of transcription 1 | 1.67 | 1.77 | −1.72 |
|
| Cyclin D1 | 1.64 | 1.57 | 1.66 |
|
| Disabled 2, mitogen-responsive phosphoprotein | 1.62 | 1.79 | n/a |
|
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon | 1.60 | n/a | 1.54 |
|
| Toll-like receptor 2 | 1.58 | 1.75 | n/a |
|
| Bone morphogenetic protein receptor, type II | 1.50 | 1.58 | n/a |
|
| Actinin, alpha 3 | −1.50 | −1.50 | n/a |
|
| Toll-like receptor 4 | −1.53 | n/a | −1.56 |
|
| Regulator of G-protein signaling 16 | −1.54 | −1.64 | n/a |
|
| Dipeptidyl-peptidase 3 | −1.56 | −1.63 | n/a |
|
| Myosin, heavy chain 7 (type I) | −1.65 | −1.87 | n/a |
|
| Inhibitor of DNA binding 1 | −1.72 | −1.53 | −1.59 |
|
| Interleukin 1 beta | −1.73 | 3.05 | −2.89 |
|
| Cyclin-dependent kinase inhibitor 1C (p57, kip2) | −1.75 | −18.10 | 2.61 |
|
| Myocyte enhancer factor 2C | −1.80 | −1.86 | −2.27 |
|
| Beta-transducin repeat containing E3 ubiquitin protein ligase | −1.89 | −1.50 | n/a |
|
| Insulin-like growth factor 1 | −1.91 | −1.71 | n/a |
|
| Transforming growth factor, beta 1 | −1.96 | 1.58 | −2.56 |
|
| Transforming growth factor, beta 1 | −2.00 | n/a | −1.84 |
|
| Muscle, skeletal, receptor tyrosine kinase | −2.03 | −4.73 | −1.90 |
|
| Myozenin 2 | −2.88 | −1.68 | n/a |
|
| Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) | −3.01 | −1.83 | −1.72 |
|
| Myosin, light chain 3, skeletal slow | −3.07 | −2.42 | −1.53 |
|
| Myogenic factor 6 | −4.13 | −3.53 | −1.94 |
|
| Myosin, heavy chain 1 (type IIx/d) | −5.89 | 1.91 | n/a |
Fold-change values of Illumina Gene array transcript subset which showed significant modulation by WT-M1 co-culture vs. WT alone compared to their fold-change values in A/J vs. WT and A/J-M1 co-culture vs. A/J alone. Only transcripts with fold-change values >1.5 and P values <0.01 were considered for analysis. ANOVA was applied to verify significance
Transcripts modulated in A/J vs. WT myoblasts co-cultured with M2a macrophages
| Gene symbol | Description | WT-M2 vs. WT | AJ vs. WT | AJ-M2 vs. AJ |
|---|---|---|---|---|
|
| Myosin, light polypeptide 2, regulatory, slow | 2.31 | n/a | 3.07 |
|
| Syndecan 4 | 2.04 | −2.16 | n/a |
|
| Nebulin-related anchoring protein | 1.98 | n/a | 2.29 |
|
| Calreticulin | 1.88 | n/a | −1.87 |
|
| Myosin light chain kinase 2 | 1.88 | n/a | n/a |
|
| Latent transforming growth factor beta binding protein 1 | 1.85 | 1.54 | n/a |
|
| Creatine kinase, muscle | 1.83 | n/a | 1.78 |
|
| Myosin binding protein C, fast type | 1.64 | 2.47 | 1.94 |
|
| Ras homolog family member B | 1.62 | n/a | 1.58 |
|
| Myosin, heavy chain 7 (type I) | 1.61 | −1.87 | n/a |
|
| Interleukin 4 | 1.59 | n/a | n/a |
|
| Ryanodine receptor 1 | 1.57 | n/a | n/a |
|
| Myozenin 2 | 1.56 | −1.69 | 1.81 |
|
| Myosin, heavy chain 7 (cardiac) | 1.52 | n/a | 2.00 |
|
| Myomesin 1 | 1.52 | n/a | 1.54 |
|
| Inhibitor of DNA binding 2 | −1.56 | 1.77 | −2.20 |
|
| Interleukin 7 | −1.57 | 1.70 | n/a |
|
| RAB27B, member RAS oncogene family | −1.61 | n/a | −1.67 |
|
| Interferon inducible GTPase 2 | −1.79 | 2.06 | −2.83 |
|
| Proteosome subunit, beta type 8 | −1.84 | 1.78 | −1.86 |
|
| Interferon gamma inducible protein 47 | −1.90 | 2.18 | −2.00 |
|
| Complement 2 | −1.95 | 2.64 | −2.40 |
|
| Caspase 1 | −2.18 | 1.98 | −2.22 |
|
| Polo-like kinase 1 | −2.29 | −2.76 | −1.68 |
|
| Interferon regulatory factor 1 | −2.91 | 1.88 | −2.43 |
|
| Guanylate binding protein 2, interferon-inducible | −3.37 | 1.60 | −2.33 |
|
| v-akt murine thymoma viral oncogene 2 | n/a | n/a | 1.51 |
|
| Glycogen synthase kinase 3 | n/a | n/a | −1.75 |
|
| Integrin, beta 1 (fibronectin receptor beta) | n/a | n/a | −2.37 |
|
| Janus kinase 1 | n/a | n/a | −1.87 |
|
| Myozenin 1 | n/a | n/a | 1.70 |
|
| Receptor (TNFRSF)-interacting serine-threonine kinase 1 | n/a | n/a | −1.51 |
|
| Vascular endothelial growth factor C | n/a | n/a | −1.50 |
|
| Solute carrier family 1 (glial high affinity glutamate transporter), member 3 | n/a | 5.59 | −1.98 |
|
| Histocompatibility 2, T region locus 23 | n/a | 4.41 | −1.66 |
|
| Interleukin 1 beta | n/a | 3.05 | −2.47 |
|
| Chemokine (C-X-C motif) ligand 16 | n/a | 2.92 | −1.74 |
|
| Collagen, type V, alpha 2 | n/a | 2.66 | −1.72 |
|
| Cytokine receptor-like factor 1 | n/a | 2.64 | −1.69 |
|
| Chemokine (C-C motif) ligand 9 | n/a | 2.00 | 1.50 |
|
| Angiopoietin-like 4 | n/a | 1.93 | −1.52 |
|
| Signal transducer and activator of transcription 1 | n/a | 1.77 | −1.61 |
|
| Tumor necrosis factor receptor superfamily, member 1b | n/a | 1.63 | −1.51 |
|
| Bone morphogenetic protein receptor 2 | n/a | 1.58 | −1.61 |
|
| Signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 | n/a | 1.57 | −1.62 |
|
| GTPase, very large interferon inducible 1 | n/a | 1.53 | −1.75 |
|
| Tumor necrosis factor (ligand) superfamily, member 9 | n/a | 1.51 | −1.57 |
|
| Protein kinase, cAMP-dependent, catalytic, alpha | n/a | −1.58 | 1.51 |
|
| ProSAPiP1 protein | n/a | −1.90 | 1.67 |
|
| Myogenic factor 6 | n/a | −3.54 | 2.62 |
|
| Muscle, skeletal, receptor tyrosine kinase | n/a | −4.73 | −1.53 |
|
| Cyclin-dependent kinase inhibitor 1C (p57, Kip2) | n/a | −18.11 | 5.52 |
Fold-change values of Illumina Gene array transcript subset which showed significant modulation by WT-M2a co-culture vs. WT alone compared to their fold-change values in A/J vs. WT and A/J-M2a co-culture vs. A/J alone. Only transcripts with fold-change values >1.5 and P values <0.01 were considered for analysis. ANOVA was applied to verify significance
Fig. 7NFκB and IL-1β in myoblast-macrophage co-cultures. a Representative Western blot showing phosphorylation of the NFκB p65 subunit in WT or A/J myoblasts either cultured alone (-), or co-cultured for 3 days with Mϕ, or M1 macrophages. b Quantitation of phospho-p65 pixel intensity in a, normalized to vinculin pixel intensity. n = 3 independent experiments. c IL-1β ELISA analysis of whole cell lysates prepared from WT (black) or A/J myotubes (white) co-cultured for 24 h with M1 or M2a macrophages. d MSD IL-1β assay performed on supernatants from WT (black) or A/J myotubes (white) co-cultured for 24 h alone, with M1 or M2a macrophages. Two-way ANOVA with Tukey post hoc test were used to calculate P values. n = 3 cultures per data point. Data are shown as means ± SEM. *P < 0.05; ***P < 0.001
Fig. 8IL-4 potentiates muscle differentiation in WT and A/J myoblasts. a Immunofluorescence staining of differentiated WT and A/J cultures treated for 72 h with 4 or 20 ng/ml of IL-4. Control cultures were treated with equal volumes of PBS (NT). Following incubation, cultures were immunostained with anti-MyoD (green) and anti-MyHC (red). Scale bar, 50 μm. b Myofusion index (expressed as % fusion). c–e Gene expression of MyoD (b), Myf5 (c), and myogenin (d) determined by qRT-PCR in WT and A/J cultures treated with indicated concentrations of IL-4. N = 4. Data are shown as means ± SEM. ANOVA with Tukey post hoc analysis, *P < 0.05; **P < 0.01; ***P < 0.005
Fig. 9Upregulated IL-1β inhibits muscle differentiation in A/J myoblasts. a Quantitation of myotube fusion in WT or A/J myoblasts treated with indicated concentrations of IL-1β for 72 h. Percent myotube fusion was calculated from MyHC-positive immunostaining. b Quantitation of MyoD-positive cells are shown as percent of total nuclei in WT or A/J myoblast cultures treated with indicated concentrations of IL-1β for 72 h. c Immunofluorescence staining of myoblast cultures after treatment with an IL-1β blocking antibody (IL-1β mAb). WT and A/J cultures were plated at equal density and treated with 4 ng/ml of IL-1β mAb for 72 h. Control cultures were treated with equimolar concentrations of mouse IgG. Fixed cultures were stained with anti-MyoD (green) and anti-MyHC (red) antibodies. d Quantitation of myotube fusion in treated cultures. e Quantitation of MyoD-positive cells in treated cultures. f–h Gene expression of MyoD (f), Myf5 (g), and myogenin (h) determined by qRT-PCR in cultures treated with indicated concentrations of IL-1β mAb. n = 3. Data are shown as means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.005